GB0225736D0 - T-Cell Independent Vaccine - Google Patents

T-Cell Independent Vaccine

Info

Publication number
GB0225736D0
GB0225736D0 GB0225736A GB0225736A GB0225736D0 GB 0225736 D0 GB0225736 D0 GB 0225736D0 GB 0225736 A GB0225736 A GB 0225736A GB 0225736 A GB0225736 A GB 0225736A GB 0225736 D0 GB0225736 D0 GB 0225736D0
Authority
GB
United Kingdom
Prior art keywords
cell independent
independent vaccine
vaccine
cell
independent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0225736A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adjuvantix Ltd
Original Assignee
Adjuvantix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjuvantix Ltd filed Critical Adjuvantix Ltd
Priority to GB0225736A priority Critical patent/GB0225736D0/en
Publication of GB0225736D0 publication Critical patent/GB0225736D0/en
Priority to PCT/GB2003/004738 priority patent/WO2004041866A1/en
Priority to AU2003285483A priority patent/AU2003285483A1/en
Ceased legal-status Critical Current

Links

GB0225736A 2002-11-05 2002-11-05 T-Cell Independent Vaccine Ceased GB0225736D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB0225736A GB0225736D0 (en) 2002-11-05 2002-11-05 T-Cell Independent Vaccine
PCT/GB2003/004738 WO2004041866A1 (en) 2002-11-05 2003-11-03 Conjugate composition comprising antibodies against cd40 or cd28
AU2003285483A AU2003285483A1 (en) 2002-11-05 2003-11-03 Conjugate composition comprising antibodies against cd40 or cd28

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0225736A GB0225736D0 (en) 2002-11-05 2002-11-05 T-Cell Independent Vaccine

Publications (1)

Publication Number Publication Date
GB0225736D0 true GB0225736D0 (en) 2002-12-11

Family

ID=9947207

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0225736A Ceased GB0225736D0 (en) 2002-11-05 2002-11-05 T-Cell Independent Vaccine

Country Status (3)

Country Link
AU (1) AU2003285483A1 (en)
GB (1) GB0225736D0 (en)
WO (1) WO2004041866A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE537813T1 (en) * 2005-09-30 2012-01-15 Lipoxen Technologies Ltd LIPOSOMAL VACCINE COMPOSITION OF A POLYSACCHARIDE ANTIGEN AND A PROTEIN ADJUVANT
US20110189208A1 (en) * 2008-09-24 2011-08-04 Andrew William Heath Tb vaccine
WO2011158019A1 (en) 2010-06-16 2011-12-22 Adjuvantix Limited Polypeptide vaccine
WO2020257317A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
WO2020257315A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Multiple antigen protein displayed adjuvant systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502437A (en) * 1997-07-17 2001-11-30 Baxter Healthcare Sa Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate
AU6677000A (en) * 1999-08-27 2001-03-26 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
CA2399940A1 (en) * 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses

Also Published As

Publication number Publication date
WO2004041866A1 (en) 2004-05-21
AU2003285483A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
GB0213622D0 (en) Vaccine Corporation
GB0202901D0 (en) Novel vaccine
GB0226722D0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0225788D0 (en) Vaccine
GB0225786D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0218921D0 (en) Novel vaccine
GB0305794D0 (en) Vaccine
GB0209878D0 (en) Vaccine
GB0225736D0 (en) T-Cell Independent Vaccine
PL376534A1 (en) Vaccine
GB0305793D0 (en) Vaccine
GB0212036D0 (en) Vaccines
EP1487852A4 (en) Anti-protozoal vaccine
GB0206595D0 (en) Vaccine
IL156434A0 (en) Vaccine
GB0226179D0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0227619D0 (en) Vaccine
GB0213364D0 (en) Vaccine
GB0229594D0 (en) Vaccine
GB0230170D0 (en) Vaccine
GB0225531D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)